IDP Idera Pharmaceuticals

Idera Pharmaceuticals (AMEX: IDP) today announced two company presentations to take place during the Biotechnology Industry Organization 2006 Annual Meeting (BIO 2006) at the McCormick Center in Chicago, IL. -- Sudhir Agrawal, D.Phil., Chief Executive Officer and Chief Scientific Officer of Idera, will take part in a panel discussion entitled "Manipulating the Immune System to Fight Cancer" 2:00 - 3:30 p.m. CDT Monday, April 9, in room 401BC as part of the Cancer track of breakout sessions at BIO 2006 -- Robert W. Karr, M.D., President of Idera, will provide an update on Idera's programs and corporate progress during a company presentation at 3:45pm CDT Monday, April 9, in Room E, McCormick Place South, Level 3, Exhibit Hall A in the Business Forum track of BIO 2006 "Manipulating the Immune System to Fight Cancer" will be chaired by Jeffrey Miller, M.D., Professor, Medicine, University of Minnesota. The panel will include representatives from academia, and pharmaceutical and biotechnology industries. The panel will discuss novel strategies to harness the immune system for therapeutic purposes by utilizing new cell therapies, vaccines and immune modulators. About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc. (AMEX: IDP) is a Cambridge, Massachusetts biotechnology company focused on the discovery, development, and commercialization of targeted immune therapies based on modulation of Toll-like Receptors (TLRs). Drug candidates targeting TLRs have broad commercial potential in the areas of oncology, infectious disease and allergy/asthma. Idera's most advanced clinical candidate, IMO-2055 (or HYB2055), is an agonist of TLR9 and is currently in a Phase 2 monotherapy trial in renal cell carcinoma, and in a Phase 1/2 chemotherapy combination therapy trial in solid tumors. Idera is collaborating with Novartis for the discovery, optimization, development and commercialization of TLR9 agonist drug candidates targeting TLR9 for asthma and allergy. Idera also has selected another TLR9 agonist, IMO-2125, as a lead candidate for infectious diseases. For more information, visit www.iderapharma.com. Forward Looking Statements This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated by such forward-looking statements, including whether products based on Idera's technology such as IMO-2055 will advance through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether the Company will complete enrollment of clinical trials in the time expected; whether, if the Company's products such as IMO-2055 receive approval, they will be successfully distributed and marketed; whether Idera's cash resources will be sufficient to fund product development and clinical trials; and such other important factors as are set forth under the caption "Risk Factors" in Idera's Quarterly Report on Form 10-K filed on March 31, 2006, which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements.